東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Quantitative decisions in drug devel...

Chuang-Stein, Christy.

FindBook

Google Book

Amazon

博客來

Quantitative decisions in drug development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Quantitative decisions in drug development/ by Christy Chuang-Stein, Simon Kirby.
作者:	Chuang-Stein, Christy.
其他作者:	Kirby, Simon.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	xv, 248 p. :ill., digital ;24 cm.
內容註:	Clinical Testing of a New Drug -- A Frequentist Decision-making Framework -- Characteristics of a Diagnostic Test -- The Parallel Between Clinical Trials and Diagnostic Tests -- Incorporating Information from Completed Trials in Future Trial Planning -- Choosing Metrics Appropriate for Different Stages of Drug Development -- Designing Proof-of-Concept Trials with Desired Characteristics -- Designing Dose-response Studies with Desired Characteristics -- Designing Confirmatory Trials with Desired Characteristics -- Designing Phase 4 Trials -- Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Discounting Prior Results to Account for Selection Bias -- Index -- Appendix.
Contained By:	Springer eBooks
標題:	Drug development - Decision making. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-46076-5
ISBN:	9783319460765

Quantitative decisions in drug development
Chuang-Stein, Christy.

Quantitative decisions in drug development[electronic resource] /by Christy Chuang-Stein, Simon Kirby. - Cham :Springer International Publishing :2017. - xv, 248 p. :ill., digital ;24 cm. - Springer series in pharmaceutical statistics,2366-8695. - Springer series in pharmaceutical statistics..

Clinical Testing of a New Drug -- A Frequentist Decision-making Framework -- Characteristics of a Diagnostic Test -- The Parallel Between Clinical Trials and Diagnostic Tests -- Incorporating Information from Completed Trials in Future Trial Planning -- Choosing Metrics Appropriate for Different Stages of Drug Development -- Designing Proof-of-Concept Trials with Desired Characteristics -- Designing Dose-response Studies with Desired Characteristics -- Designing Confirmatory Trials with Desired Characteristics -- Designing Phase 4 Trials -- Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Discounting Prior Results to Account for Selection Bias -- Index -- Appendix.

This book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.

ISBN: 9783319460765

Standard No.: 10.1007/978-3-319-46076-5doiSubjects--Topical Terms:

3242417
Drug development
--Decision making.

LC Class. No.: RM301.25 / .C49 2017

Dewey Class. No.: 615.19

Quantitative decisions in drug development
LDR:03091nmm a2200337 a 4500 001 2100597
003 DE-He213
005 20170525114034.0
006 m d
007 cr nn 008maaau
008 180119s2017 gw s 0 eng d
020 $a 9783319460765 $q (electronic bk.)
020 $a 9783319460758 $q (paper)
024 7 $a 10.1007/978-3-319-46076-5 $2 doi
035 $a 978-3-319-46076-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .C49 2017
072 7 $a PBT $2 bicssc
072 7 $a MBNS $2 bicssc
072 7 $a MED090000 $2 bisacsh
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .C559 2017
100 1 $a Chuang-Stein, Christy. $3 3242416
245 1 0 $a Quantitative decisions in drug development $h [electronic resource] / $c by Christy Chuang-Stein, Simon Kirby.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xv, 248 p. : $b ill., digital ; $c 24 cm.
490 1 $a Springer series in pharmaceutical statistics, $x 2366-8695
505 0 $a Clinical Testing of a New Drug -- A Frequentist Decision-making Framework -- Characteristics of a Diagnostic Test -- The Parallel Between Clinical Trials and Diagnostic Tests -- Incorporating Information from Completed Trials in Future Trial Planning -- Choosing Metrics Appropriate for Different Stages of Drug Development -- Designing Proof-of-Concept Trials with Desired Characteristics -- Designing Dose-response Studies with Desired Characteristics -- Designing Confirmatory Trials with Desired Characteristics -- Designing Phase 4 Trials -- Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Discounting Prior Results to Account for Selection Bias -- Index -- Appendix.
520 $a This book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.
650 0 $a Drug development $x Decision making. $3 3242417
650 0 $a Drug development $x Economic aspects. $3 3242418
650 1 4 $a Statistics. $3 517247
650 2 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 891086
650 2 4 $a Biostatistics. $3 1002712
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
650 2 4 $a Quality Control, Reliability, Safety and Risk. $3 891027
700 1 $a Kirby, Simon. $3 746207
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Springer series in pharmaceutical statistics. $3 2203618
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46076-5
950 $a Mathematics and Statistics (Springer-11649)